Bavarian Nordic Spon (BVNRY) Receives Hold Rating from Maxim Group

Maxim Group reiterated their hold rating on shares of Bavarian Nordic Spon (OTCMKTS:BVNRY) in a research report sent to investors on Friday.

Shares of Bavarian Nordic Spon (OTCMKTS:BVNRY) traded down 46.43% during midday trading on Friday, reaching $12.16. The company had a trading volume of 2,675 shares. The stock’s 50 day moving average is $11.70 and its 200-day moving average is $11.70. Bavarian Nordic Spon has a 12-month low of $10.56 and a 12-month high of $17.33. The stock has a market capitalization of $1.15 billion and a PE ratio of 31.75.

Bavarian Nordic Spon (OTCMKTS:BVNRY) last posted its quarterly earnings results on Friday, August 25th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.07). Bavarian Nordic Spon had a return on equity of 11.36% and a net margin of 15.48%. The firm had revenue of $58.68 million for the quarter, compared to analyst estimates of $50.65 million.

ILLEGAL ACTIVITY WARNING: This article was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://transcriptdaily.com/2017/09/16/bavarian-nordic-spon-bvnry-receives-hold-rating-from-maxim-group.html.

Bavarian Nordic Spon Company Profile

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings for Bavarian Nordic Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic Spon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply